January - 2025

top of page

Sage Group News

Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody

Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody

Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody

Starrygene ( https://www.starrygene.com/ ) is a clinical stage biotechnology company based in China, focused on XMVA09, a novel...

Opportunity to License SP16, A Novel Treatment For Acute Kidney Injury (AKI)

Opportunity to License SP16, A Novel Treatment For Acute Kidney Injury (AKI)

Opportunity to License SP16, A Novel Treatment For Acute Kidney Injury (AKI)

Serpin Pharma (“Serpin”) is an anti-inflammatory/immunology company focused on developing its patented (CoM and use) SP-16 LRP1 agonist...

Opportunity to Partner Novel VHH Multi-Specific Antibodies Targeted at Solid and Hematologic Tumors

Opportunity to Partner Novel VHH Multi-Specific Antibodies Targeted at Solid and Hematologic Tumors

Opportunity to Partner Novel VHH Multi-Specific Antibodies Targeted at Solid and Hematologic Tumors

Our client, Starmab Biomed Inc (“Starmab” or the “Company”), is a US/China-based biotech company headquartered at Beijing Zhongguancun...

bottom of page